COV-PREG-COAG V1
Research type
Research Study
Full title
International Registry on Pregnancy and COVID-19 Associated Coagulopathy and Thrombosis (COV-PREG-COAG)
IRAS ID
286712
Contact name
Rezan Abdul-Kadir
Contact email
Sponsor organisation
Royal Free London NHS Foundation Trust
Duration of Study in the UK
2 years, 11 months, days
Research summary
Novel coronavirus (SARS-CoV-2), previously known as 2019-nCoV, which causes COVID-19, has affected 2,000,269 cases with 130,398 deaths worldwide. This is a respiratory illness, the symptoms of which usually include cough, high temperature and shortness of breath, and while short-term data based on small case-series suggests that pregnant individuals are not at higher risk of illness than the non-pregnant population, little is known about the impact COVID-19 will have on affected pregnancies and their maternal and fetal/neonatal outcomes.
Abnormalities in blood test such raised D-Dimer, prolonged clotting time and abnormal platelet count were associated with worse prognosis in COVID-19 patients. Furthermore, an increased risk of blood clots was also reported in severe disease. The extent and frequency of such clotting abnormalities in COVID-19 during pregnancy are currently unknown. The effect of other coronaviruses such as SARS and MERS13-15 on mother’s health during pregnancy are known. But we do not know the effect on the mother and fetus with SARS-CoV-2 infection. Similarly, there are questions with respect to the risk of blood clots in a COVID-19 affected pregnancy, the use of therapy such blood thinning medications, corticosteroids and the use and safety of antiviral therapies in the context of COVID-19 and pregnancy.
The aim of this registry is to better understand the effect of COVID-19 infection during pregnancy and safety of the available treatment in pregnant or postpartum women. This will help gain knowledge to improve the medical care of pregnancies affected by COVID-19 infection in the future.
This is an International observational registry, and no experimental drugs will be tested.REC name
East of Scotland Research Ethics Service REC 2
REC reference
21/ES/0013
Date of REC Opinion
5 Jul 2021
REC opinion
Further Information Favourable Opinion